At a state-of-the-art facility in Thousand Oaks, California, drugmaker Amgen Inc. is perfecting the art of copying others, and it must work fast because copycats are already coming for Amgen's drugs.
At a state-of-the-art facility in Thousand Oaks, California, drugmaker Amgen Inc. is perfecting the art of copying others.
The 25,000-square-foot (2,300-square-meter) plant is filled with stainless steel tanks that can hold as much as 2000 liters, each covered with a multitude of dials, buttons and protruding pipes. This is where Amgen tests ways to grow Chinese hamster ovary cells to make its own drugs -- and imitations of other companies’ medicine.
Taking advantage of a 2010 US law, Amgen has prepared one of the most ambitious pipelines in the industry to develop drugs that mimic its rivals’ biologic treatments. The company plans to have as many as 5 such products, known as biosimilars, on the market by 2019.
Amgen must act fast, because copycats are coming for its drugs, too. Thanks to a regulatory ruling last Friday, the biotech company’s cancer drug, Neupogen, will be the first biologic medicine in the US to face competition from a government-approved biosimilar. That imitation, made by Novartis AG, could represent a threat to more than $7 billion in annual revenue for Neupogen and related medicine Amgen sells.
Read more at Bloomberg: http://bloom.bg/1GojoKo
CMS' 340B Repayment Proposal May Harm Vulnerable Hospitals, Reward Those With Higher Revenues
April 26th 2024The 340B hospitals not receiving an offsetting lump-sum payment from CMS following 2018-2022 cuts later ruled unlawful are disproportionately rural, publicly owned, and nonacademic, according to a new study.
Read More
Navigating Health Policy in an Election Year: Insights From Dr Dennis Scanlon
April 2nd 2024On this episode of Managed Care Cast, we're talking with Dennis Scanlon, PhD, the editor in chief of The American Journal of Accountable Care®, about prior authorization, price transparency, the impact of health policy on the upcoming election, and more.
Listen
What We’re Reading: Abortion Privacy Rules; Alzheimer Drug Hurdles; Nursing Home Staffing Overhaul
April 23rd 2024New health privacy rules aim to protect patients and providers in an evolving abortion landscape; some physicians express concerns about efficacy, risks, and entrenched beliefs in treating Alzheimer disease; CMS addresses longstanding staffing deficits in nursing homes.
Read More